Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models

被引:10
作者
Arnal, Jean-Francois [1 ]
Valera, Marie-Cecile
Payrastre, Bernard
Lenfant, Francoise
Gourdy, Pierre
机构
[1] Univ Toulouse, Fac Med, INSERM, U1048,I2MC, F-31432 Toulouse, France
关键词
VASCULAR INJURY RESPONSE; HORMONE-THERAPY; POSTMENOPAUSAL WOMEN; ACTIVATION-FUNCTION; PROMOTER-CONTEXT; ER-ALPHA; BETA; ESTRADIOL; DISEASE; RISK;
D O I
10.1016/j.thromres.2012.08.261
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ancestral status of estrogen receptor (ER) in the family of the steroid receptors has probably contributed to the pleiotropic actions of estrogens, and in particular of 17 beta-estradiol (E2). Indeed, in addition to their well described role in sexual development and reproduction, they influence most of the physiological processes. The pathophysiological counterpart of these actions includes several highly beneficial effects such as prevention of osteoporosis, atheroma and type 2 diabetes,. However, estrogens also promotes two deleterious actions : the stimulation of the proliferation of the epithelium of two sex targets : uterus and breast, favoring an increase in risk of epithelial cancer in these two tissues. These actions are mediated by the activation of ER alpha (ERa) and beta (ER beta), which regulate target gene transcription (genomic action) through two independent activation functions AF-1 and AF-2, but can also elicit rapid membrane initiated steroid signals. Although ER beta plays an important role in the central nervous system and in the heart, ERa appears to play a prominent role in most of the other tissues. One major challenge consists in uncoupling some beneficial actions from other deleterious ones, i. e. selective ER modulation. Tamoxifen and raloxifen are beneficial to prevent the recurrence of breast cancer, and mimic estrogen action mainly on bone, but their effets on atheroma and on type 2 diabetes are if any marginal. These last years, several labs, and in particular our lab, have attempted: 1) To perform an in vivo molecular "dissection" of ERa, allowing the uncoupling of some of its actions, and potentially paving the way to optimized selective ER modulators. (reviewed in Arnal JF, et al. Br J Pharmacol. 2012; 165: 57-66). 2) To describe an unexpected action of E2 treatment at the level of platelet responses in mice, that protects the animals from thromboembolism through the haematopoietic ERa. (Valera MC et al. Blood. 2012, in press). (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:S7 / S11
页数:5
相关论文
共 62 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Palmitoylation-dependent estrogen receptor α membrane localization:: Regulation by 17β-estradiol
    Acconcia, F
    Ascenzi, P
    Bocedi, A
    Spisni, E
    Tomasi, V
    Trentalance, A
    Visca, P
    Marino, M
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (01) : 231 - 237
  • [3] Prior hormone therapy and breast cancer risk in the Women's Health initiative randomized trial of estrogen plus progestin
    Anderson, Garnet L.
    Chlebowski, Rowan T.
    Rossouw, Jacques E.
    Rodabough, Rebecca J.
    McTiernan, Anne
    Margolis, Karen L.
    Aggerwal, Anita
    Curb, J. David
    Hendrix, Susan L.
    Hubbell, F. Allan
    Khandekar, Jamardan
    Lane, Dorothy S.
    Lasser, Norman
    Lopez, Ana Maria
    Potter, JoNell
    Ritenbaugh, Cheryl
    [J]. MATURITAS, 2006, 55 (02) : 103 - 115
  • [4] Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
    Anderson, GL
    Limacher, M
    Assaf, AR
    Bassford, T
    Beresford, SAA
    Black, H
    Bonds, D
    Brunner, R
    Brzyski, R
    Caan, B
    Chlebowski, R
    Curb, D
    Gass, M
    Hays, J
    Heiss, G
    Hendrix, S
    Howard, BV
    Hsia, J
    Hubbell, A
    Jackson, R
    Johnson, KC
    Judd, H
    Kotchen, JM
    Kuller, L
    LaCroix, AZ
    Lane, D
    Langer, RD
    Lasser, N
    Lewis, CE
    Manson, J
    Margolis, K
    Ockene, J
    O'Sullivan, MJ
    Phillips, L
    Prentice, RL
    Ritenbaugh, C
    Robbins, J
    Rossouw, JE
    Sarto, G
    Stefanick, ML
    Van Horn, L
    Wactawski-Wende, J
    Wallace, R
    Wassertheil-Smoller, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14): : 1701 - 1712
  • [5] Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERβ-null mutant
    Antal, Maria Cristina
    Krust, Andree
    Chambon, Pierre
    Mark, Manuel
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (07) : 2433 - 2438
  • [6] Genetic and pharmacologic strategies to determine the function of estrogen receptor α and estrogen receptor β in the cardiovascular system
    Arias-Loza, Paula Anahi
    Jazbutyte, Virginija
    Pelzer, Theo
    [J]. GENDER MEDICINE, 2008, 5 : S34 - S45
  • [7] Estrogens in vascular biology and disease:: where do we stand today?
    Arnal, Jean-Francois
    Scarabin, Pierre-Yves
    Tremollieres, Florence
    Laurell, Henrik
    Gourdy, Pierre
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (05) : 554 - 560
  • [8] Estrogen Receptors and Endothelium
    Arnal, Jean-Francois
    Fontaine, Coralie
    Billon-Gales, Audrey
    Favre, Julie
    Laurell, Henrik
    Lenfant, Francoise
    Gourdy, Pierre
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (08) : 1506 - 1512
  • [9] Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001
  • [10] Hormones and heart disease in women: The timing hypothesis
    Barrett-Connor, Elizabeth
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 166 (05) : 506 - 510